Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aw, S. T.
Right arrow Articles by Halmagyi, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aw, S. T.
Right arrow Articles by Halmagyi, G. M.
Related Collections
Right arrow All Health Services Research
Right arrow Diagnostic test assessment
Right arrow All Neurotology
Right arrow All clinical neurophysiology
NEUROLOGY 2008;71:1776-1782
© 2008 American Academy of Neurology

Gentamicin vestibulotoxicity impairs human electrically evoked vestibulo-ocular reflex

S. T. Aw, PhD, M. J. Todd, MBiomedE, G. E. Aw, MBBS, K. P. Weber, MD and G. M. Halmagyi, MD

From the Central Clinical School (S.T.A.), Faculty of Medicine, University of Sydney; and Institute of Clinical Neuroscience (S.T.A., M.J.T., G.E.A., K.P.W., G.M.H.), Royal Prince Alfred Hospital, Sydney, Australia.

Address correspondence and reprint requests to Dr. Swee T. Aw, Institute of Clinical Neuroscience, Royal Prince Alfred Hospital, Camperdown NSW 2050, Sydney, Australia sweea{at}icn.usyd.edu.au

Background: Electrical vestibular stimulation is believed to directly activate the vestibular afferents to mediate an electrically evoked vestibulo-ocular reflex (eVOR). Gentamicin, an aminoglycoside antibiotic, induces vestibulotoxicity by hair cell damage and death.

Objective: To determine if human eVOR is impaired by hair cell damage and death in systemic gentamicin vestibulotoxicity (GV).

Methods: Three-dimensional binocular eye movements evoked by bilateral, bipolar, 100 msec direct current-step at intensities of 0.9, 2.5, 5.0, 7.5, and 10.0 mA were recorded with dual-search coils in 12 GV patients, and the results were compared to 13 healthy subjects.

Results: Normal eVOR was predominantly torsional, comprising phasic eVOR initiation and cessation acceleration pulses at 9 msec latency after current onset and offset, with a tonic eVOR velocity-step during the 100 msec intervening period of maintained current. Normal phasic eVOR increased, while tonic eVOR scaled linearly, with current intensity. GV impaired phasic eVOR more severely than tonic eVOR, and prolonged the latency to 12–13 msec. In patients without mechanical response to vestibular tests, phasic eVOR was reduced to one-fifth of normal amplitude, doubled in duration, had reduced ability to vary with current intensity, and threshold was increased. Tonic eVOR was reduced to one-third of normal, but still scaled linearly with current intensity. Patients, who retained partial mechanical responses to vestibular tests, had phasic eVOR impairment without tonic eVOR abnormality.

Conclusion: Impairment of evoked vestibulo-ocular reflex (eVOR) in gentamicin vestibulotoxicity (GV) suggests that vestibular hair cells, activated by electrical stimulation, mediate the eVOR. Abnormalities of the eVOR, especially the phasic component, might be a marker of vestibular injury in GV.

GLOSSARY: eVOR = electrically evoked vestibulo-ocular reflex; EVS = electrical (galvanic) vestibular stimulation; GV = gentamicin vestibulotoxicity.


Supplemental data at www.neurology.org

Supported by National Health and Medical Research Council Australia, University of Sydney, The Garnett Passe and Rodney Williams Memorial Foundation, The Clive and Vera Ramaciotti Foundations, Neurology Trustees Royal Prince Alfred Hospital, and Brain Foundation.

Disclosure: The authors report no conflicts of disclosures.

Received April 13, 2008. Accepted in final form August 26, 2008.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.